Immunization of woodchucks with adjuvanted sHDAg (p24): Immune response and outcome following challenge

Vaccine

Volumn 22, Issue 3-4, 2004, Pages 457-466

  D'Ugo, Emilio ^a   Paroli, Marino ^b   Palmieri, Giampiero ^c   Giuseppetti, Roberto ^a   Argentini, Claudio ^a   Tritarelli, Elena ^a   Bruni, Roberto ^a   Barnaba, Vincenzo ^b   Houghton, Michael ^d   Rapicetta, Maria ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adjuvants; Hepatitis delta virus (HDV); Woodchuck hepatitis virus (WHV); Woodchuck immunization

Indexed keywords

ANTIGEN P24; FREUND ADJUVANT; HEPATITIS DELTA ANTIGEN; HEPATITIS DELTA VIRUS VACCINE; HEPATITIS VACCINE; IMMUNOLOGICAL ADJUVANT; NUCLEOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DOSE RESPONSE; DRUG DOSE REGIMEN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LIVER FUNCTION TEST; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS SURVIVAL; WOODCHUCK;

EID: 10744221831     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.07.001     Document Type: Article

References (34)

1. Rizzetto M. The delta agent. Hepatology. 3:1993;729-737.
2. Colombo M., Cambieri R., Rumi M.G., Ronchi G., Del Ninno E., De Franchis R. Long-term delta superinfection in hepatitis B surface antigen carriers and its relationship to the course of chronic hepatitis. Gastroenterology. 85:1983;235-239.
3. Taylor J., Mason W., Summers J.et al. Replication of human hepatitis delta virus in primary cultures of woodchuck hepatocytes. J. Virol. 61:1987;2891-2895.
4. Maddrey W.C. Hepatitis B: an important public health issue. Clin. Lab. 47:2001;51-55.
5. Fattovich G., Boscaro S., Noventa F.et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J. Infect. Dis. 155:1987;931-935.
6. Fattovich G., Giustina G., Christensen E.et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 46:2000;420-426.
7. Gaudin J.L., Faure P., Godinot H., Gerard F., Trepo C. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver. 15:1995;45-52.
8. Wolters L.M., van Nunen A.B., Honkoop P.et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J. Viral. Hepatol. 7:2000;428-434.
9. Weiner A.J., Choo Q.L., Wang K.S., Govindarajan S.et al. A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta. J. Virol. 62:1988;594-599.
10. Karayiannis P., Saldahana J., Monjardino J.et al. Immunization of woodchucks with recombinant hepatitis delta antigen does not protect against hepatitis delta virus infection. Hepatology. 12:1990;1125-1128.
11. Negro F., Shapiro M., Satterfield W.C., Gerin J.L., Purcell R.H. Reappearance of hepatitis D virus (HDV) replication in chronic hepatitis B virus carrier chimpanzees rechallenged with HDV. J. Infect. Dis. 160:1989;567-571.
12. Karayiannis P., Saldanha J., Jackson A.M.et al. Partial control of hepatitis delta virus superinfection by immunization of woodchucks (Marmota monax) with hepatitis delta antigen expressed by a recombinant vaccinia or baculovirus. J. Med. Virol. 41:1993;210-214.
13. Karayiannis P., Goldin R., Luther S., Carman W.F., Monjardino J., Thomas H.C. Effect of cyclosporin-A in woodchucks with chronic hepatitis delta virus infection. J. Med. Virol. 36:1992;316-321.
14. Roingeard P., Dubois F., Marcellin P.et al. Persistent delta antigenaemia in chronic delta hepatitis and its relation with human immunodeficiency virus infection. J. Med. Virol. 38:1992;191-194.
15. + T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J. Virol. 71:1997;2241-2251.
16. Ponzetto A., Eckart M., D'Urso N.et al. Towards a vaccine for the prevention of hepatitis delta virus superinfection in HBV carriers. Prog. Clin. Biol. Res. 382:1993;207-210.
17. Mrsny R.J. Adjuvants and delivery issues related to immunization: a survey of the recent patent literature. J. Drug Target. 6:1998;243-249.
18. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 17:1999;1075-1081.
19. Bonino F., Brunetto M.R., Negro F., Smedile A., Ponzetto A. Hepatitis delta virus, a model of liver cell pathology. J. Hepatol. 13:1991;260-266.
20. Shanmuganathan S., Waters J.A., Karayiannis P., Thursz M., Thomas H.C. Mapping of the cellular immune responses to woodchuck hepatitis core antigen epitopes in chronically infected woodchucks. J. Med. Virol. 52:1997;128-135.
21. L-lysine. Synthesis of the carrier and pharmacological properties of the conjugate. J. Hepatol. 26:1997;253-259.
22. Ciccaglione AR, Rapicetta M, Fabiano A, Argentini C, Silvestro M, Giuseppetti R, Varono F, D'Urso N, Dinolfo L, Morgando A, et al. Chronic infection in woodchucks infected by a cloned hepatitis delta virus. Arch Virol 1993;Suppl 8:15-21.
23. Menne S., Maschke J., Tolle T., Kreuzfelder E., Grosse-Wilde H., Roggendorf M. Determination of peripheral blood mononuclear cell responses to mitogens and woodchuck hepatitis virus core antigen in woodchucks by 5-bromo-2′-deoxyuridine or 2[3H] adenine incorporation. Arch. Virol. 142:1997;511-521.
24. Ishak K., Baptista A., Bianchi L.et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22:1995;696-699.
25. Fiedler M., Lu M., Siegel F., Whipple J., Roggendorf M. Immunization of woodchucks (Marmota monax) with hepatitis delta virus DNA vaccine. Vaccine. 19:2001;4618-4626.
26. Karayiannis P., Saldanha J., Monjardino J.et al. Immunization of woodchucks with recombinant hepatitis delta antigen does not protect against hepatitis delta virus infection. Hepatology. 12:1990;1125-1128.
27. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1:2001;209-219.
28. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6:1995a;277-296.
29. Dupuis M., McDonald D.M., Ott G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine. 18:1999;434-439.
30. O'Hagan D.T., Ugozzoli M., Barackman J.et al. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. Vaccine. 18:2000;1793-1801.
31. Traquina P., Morandi M., Contorni M., Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis. 174:1996;1168-1175.
32. Ott G., Barchfeld G.L., Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine. 13:1995;1557-1562.
33. Verschoor E.J., Mooij P., Oostermeijer H.et al. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. J. Virol. 73:1999;3292-3300.
34. + regulatory T cells. J. Exp. Med. 194:2001;847-853.